title: A phase II trial of chlorambucil in non-small cell lung cancer.
abstract: A Phase II trial of high-dose chlorambucil at 108 mg/m2 was undertaken in non-small cell lung cancer. No complete or partial objective responses were observed, and significant toxicity, including nausea, vomiting, and seizures, was noted. Chlorambucil at this dose and schedule of administration is not recommended for the treatment of non-small cell lung cancer.
authors.affiliation: Division of Medical Oncology, University of Louisville School of Medicine, KY 40292.
authors.forename: P S
authors.initials: PS
authors.lastname: Gentile
authors.forename: T M
authors.initials: TM
authors.lastname: Woodcock
authors.forename: M S
authors.initials: MS
authors.lastname: Blumenreich
authors.forename: B E
authors.initials: BE
authors.lastname: Epremian
authors.forename: J
authors.initials: J
authors.lastname: Seeger
authors.forename: S P
authors.initials: SP
authors.lastname: Sheth
authors.forename: J T
authors.initials: JT
authors.lastname: Hamm
authors.forename: E J
authors.initials: EJ
authors.lastname: Sherrill
authors.forename: J C
authors.initials: JC
authors.lastname: Allegra
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002699:Chlorambucil / Q000009:adverse effects*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D002699:Chlorambucil